Gapping up
In reaction to strong earnings/guidance:
- WTS +11.9%, CRNT +11.3%, CHEK +7.3%, HAIR +7.1%, CYOU +5.5%, SRC +3.5%, DO +3.4%, WRK +3%, BRK.B +2.8%, FOLD +2.1%, NS +1.9%, ACRX +1.3%, OHI +1.2%
M&A news:
- DWCH +34.7% ( to be acquired by Altair (ALTR) for $13.10/share in cash)
- CZR +3.6% (MGM Resorts considering merger with Caesars Entertainment (CZR), according to NY Post) .
Select metals/mining stocks trading higher:
- AU +2.8%, RIO +1.6%, BBL +1.6%, SBGL +1.2%
Other news:
- INFI +10.2% (Infinity Pharmaceutical & Bristol-Myers Squibb (BMY) announce clinical trial collaboration to evaluate Opdivo in combination with IPI-549 in patients with advanced urothelial cancer)
- SAGE +6.9% (confirms FDA Advisory Committee voted 17-1 in support of benefit-risk profile of ZULRESSO injection for treatment of postpartum depression)
- MEIP +5.9% (executes a license agreement granting Kyowa Hakko Kirin exclusive rights to develop and commercialize ME-401 in Japan)
- MFGP +5.6% (announces the appointment of Brian McArthur-Muscroft as Chief Financial Officer; FY18 constant currency revenue guidance trending toward better end of range; to recommence buy-back program)
- AXL +4.4% (modestly rebounding after last week's 24% decline)
- SPOT +2.2% (authorizes $1 bln stock repurchase program)
- LLY +2.1% (presents initial results from real-world EMPRISE study)
- GE +1.2% (CEO Larry Culp discloses the purchase of 225k shares at $9.73)
Analyst comments:
- UAA +2.4% (upgraded to Overweight from Neutral at Piper Jaffray)
- FCAU +1.1% (upgraded to Buy from Hold at Societe Generale)
- FATE +7.8% (initiated with a Buy at Jefferies)